Loading stock data…
IBRX
$7.11+0.01 (+0.14%)
Market ClosedLast close May 1
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmunityBio, Inc. in the Healthcare sector is trading at $7.11. The stock is currently 43% below its 52-week high of $12.43, remaining 65.3% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why IBRX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.11
Potential Upside
5%
Whystock Fair Value$7.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$15.75+121.5%
Range$12.00 – $23.00
Fundamentals
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
73.35%
Volume
Today's trading volume
7.62M
Recent News
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026. Product revenue in the quarter was up 168% year over year to $44.2 million. The increase […]
What Makes ImmunityBio (IBRX) a New Buy Stock
ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy?
ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional partners Biopharma and Cigalah Healthcare and its local subsidiary. This marks one of the first commercial rollouts of ANKTIVA for both bladder and lung cancer in the Middle East and North Africa, a region facing a rapidly growing cancer burden and rising demand for additional treatment...
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best biotech stocks on our list. TheFly reported on April 21 that ImmunityBio, Inc. (NASDAQ:IBRX) announced that its immunotherapy ANKTIVA has begun commercial availability in Saudi Arabia, with initial patients already identified for treatment. […]
Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look”
ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round, Cramer said: You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but […]